XRTX vs. SNPX, ALZN, FWBI, SONN, KZIA, CING, OGEN, PXMD, NEXI, and LIPO
Should you be buying Xyratex stock or one of its competitors? The main competitors of Xyratex include Synaptogenix (SNPX), Alzamend Neuro (ALZN), First Wave BioPharma (FWBI), Sonnet BioTherapeutics (SONN), Kazia Therapeutics (KZIA), Cingulate (CING), Oragenics (OGEN), PaxMedica (PXMD), NexImmune (NEXI), and Lipella Pharmaceuticals (LIPO). These companies are all part of the "pharmaceutical preparations" industry.
Synaptogenix (NASDAQ:SNPX) and Xyratex (NASDAQ:XRTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations.
Xyratex's return on equity of -22.50% beat Synaptogenix's return on equity.
10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 0.2% of Xyratex shares are owned by institutional investors. 4.3% of Synaptogenix shares are owned by company insiders. Comparatively, 6.9% of Xyratex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Xyratex received 155 more outperform votes than Synaptogenix when rated by MarketBeat users. Likewise, 63.41% of users gave Xyratex an outperform vote while only 50.00% of users gave Synaptogenix an outperform vote.
Xyratex is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.
In the previous week, Xyratex had 1 more articles in the media than Synaptogenix. MarketBeat recorded 1 mentions for Xyratex and 0 mentions for Synaptogenix. Xyratex's average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.
Xyratex has a consensus target price of $14.00, indicating a potential upside of 428.30%. Given Synaptogenix's higher probable upside, analysts plainly believe Xyratex is more favorable than Synaptogenix.
Synaptogenix has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Xyratex has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
Summary
Xyratex beats Synaptogenix on 8 of the 13 factors compared between the two stocks.
Get Xyratex News Delivered to You Automatically
Sign up to receive the latest news and ratings for XRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
